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Abstract
CDK8 and its paralog CDK19, in complex with CCNC, MED12 and MED13, are transcriptional 
regulators that mediate several carcinogenic pathways and the chemotherapy-induced tumor-
supporting paracrine network. Following up on our previous observation that CDK8, CDK19 and 
CCNC RNA expression is associated with shorter relapse-free survival (RFS) in breast cancer, we 
now found by immunohistochemical analysis that CDK8/19 protein is overexpressed in invasive 
ductal carcinomas relative to non-malignant mammary tissues. Meta-analysis of transcriptomic 
data revealed that higher CDK8 expression is associated with shorter RFS in all molecular 
subtypes of breast cancer. These correlations were much stronger in patients who underwent 
systemic adjuvant therapy, suggesting that CDK8 impacts the failure of systemic therapy. The 
same associations were found for CDK19, CCNC and MED13. In contrast, MED12 showed the 
opposite association with a longer RFS. The expression levels of CDK8 in breast cancer samples 
were directly correlated with the expression of MYC, as well as CDK19, CCNC and MED13 but 
inversely correlated with MED12. CDK8, CDK19 and CCNC expression was strongly increased 
and MED12 expression was decreased in tumors with mutant p53. Gene amplification is the most 
frequent type of genetic alterations of CDK8, CDK19, CCNC and MED13 in breast cancers (9.7% 
of which have amplified MED13), whereas point mutations are more common in MED12. These 
results suggest that the expression of CDK8 and its interactive genes has a profound impact on the 
response to adjuvant therapy in breast cancer in accordance with the role of CDK8 in 
chemotherapy-induced tumor-supporting paracrine activities.
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BREAST CANCER BIOMARKERS GUIDE THE CHOICE OF THERAPY
Breast cancer remains a major health challenge, with 234,190 estimated new cases in the US 
in 2015 and 40,730 expected to die from the disease [1]. Several biomarkers have long been 
used to guide the choice of therapy in breast cancer. In particular, expression of estrogen 
receptor and progesterone receptor is used as an indication for hormone therapy, whereas 
HER2/Neu overexpression indicates the use of HER2-targeted agents. Research on new 
biomarkers for early detection and prediction of post-surgical recurrence and treatment 
response in breast cancer is rapidly expanding [2]. This research has received a great boost 
from the accumulation of transcriptomic data in breast cancer and the powerful 
bioinformatics methods for its processing, which, after validation, resulted in the 
development of RNA-based multigene tests to predict breast cancer recurrence. These tests, 
such as Oncotype DX and MammaPrint were found to have a positive impact on the 
selection of adjuvant therapy [2]. Several potential biomarkers are being actively 
investigated for the prediction of systemic therapy response, such as polymorphic variants or 
mutations in CYP2D6 or PIK3CA and the expression of RARA, STAT3, Lin28 and several 
microRNAs but none of these biomarkers have yet been verified for diagnostic use [2]. 
There is continuous need to identify additional biomarkers that can be added to multigene 
tests in order to guide therapeutic choices more precisely. In the present study, we have 
investigated the expression of genes of the transcription-regulatory CDK8 complex, recently 
identified as a pleiotropic mediator of carcinogenesis and chemotherapy failure, as potential 
new biomarkers of prognosis and therapy response in breast cancer.
CDK8/19: TRANSCRIPTION-REGULATING ONCOGENIC KINASES
Cyclin-dependent kinase 8 (CDK8) and its closely related paralog CDK19 (80% identity) 
are transcription-regulating serine/threonine kinases that, unlike better-known members of 
the CDK family, such as CDK1 (CDC2), CDK2 or CDK4/6, do not play a general role in 
cell cycle progression [3]; CDK8 depletion does not inhibit the growth of normal cells [4]. 
CDK19 is not expressed as universally as CDK8 but transcriptional effects of CDK8 and 
CDK19 have been shown to be largely overlapping (albeit non-identical) [5]. CDK8 and 
CDK19 are alternative subunits of the regulatory CDK module of the Mediator complex that 
links transcription-initiating factors with RNA Polymerase II (Pol II). The other components 
of the CDK module are Cyclin C (CCNC) (the regulatory subunit of CDK8/19 kinase), 
MED12 and MED13 [3]. The CDK module was at first implicated in the inhibition of 
transcription [6–8], and this repressive effect was reported in some systems to be 
independent of the kinase activity of CDK8 [7]. On the other hand, recent studies have 
identified multiple roles of CDK8 as a positive regulator of transcription initiated by various 
signals [3]. The CDK module is capable of phosphorylating the C-terminal domain (CTD) 
of Pol II, which enables the elongation of transcription [9,10]. CDK8, however, is required 
for Pol II CTD phosphorylation only in a context-specific manner, at silent genes when they 
become activated by transcription-initiating signals, as demonstrated for genes induced by 
serum [9] or HIF1A [10]. As a result of this selective activity, CDK8/19 inhibition has little 
effect on most cell types under homeostatic conditions [11] but it prevents transcriptional 
reprogramming triggered by various signals [9,10].
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CDK8/19-mediated transcriptional reprogramming is especially pertinent in cancer, where 
CDK8 was identified as a positive transcriptional regulator in cancer-relevant signaling 
pathways, including Wnt/β-catenin [12], the serum response network [9], the TGFβ 
signaling pathway [13] and HIF1A-mediated response to hypoxia [10,14]. CDK8 has been 
identified as an oncogene, which is amplified in a substantial fraction of colon cancers [12]. 
CDK8 has also been implicated in melanomagenesis [15], associated with the cancer stem 
cell phenotype [16] and with shorter survival in colorectal cancers [17]. Our work has 
identified CDK8 as a mediator of damage-induced tumor-promoting paracrine activities of 
both tumor and normal cells; as a consequence, CDK8/19 inhibition increases the efficacy of 
chemotherapy [11]. Although the oncogenic role of CDK8 has been firmly established, a 
recent report has identified its binding partner CCNC as a haploinsufficient tumor 
suppressor in T-cell leukemia [18]. The latter effect of CCNC has been linked to the 
phosphorylation of Notch1 [18], which in its turn is known to possess a mixture of tumor-
suppressive and tumor-promoting activities [19].
In our previous study, using the KM-plotter online survival analysis tool [20], we have 
analyzed survival associations of the expression of CDK8, CDK19 and CCNC in a 
compilation of Affymetrix microarray gene expression data and found that higher CDK8, 
CDK19 and CCNC expression was correlated with shorter Relapse Free Survival (RFS) in 
breast and ovarian cancers, with the strongest association observed in breast cancers [11]. 
We have now extended this analysis by analyzing CDK8/19 protein expression in benign 
and malignant breast tissues and by extensive analysis of genomic and transcriptomic data 
on CDK8, CDK19 and their binding partners CCNC, MED12 and MED13 in breast cancer.
IMMUNOHISTOCHEMICAL ANALYSIS OF CDK8/19 PROTEIN EXPRESSION 
IN BENIGN AND MALIGNANT BREAST TISSUES
Since the paracrine effects of CDK8/19 are exerted in both tumor and normal cells, the 
microarray data [11] obtained from bulk tissue samples could reflect CDK8/19 expression 
either in the tumor or in the stromal cells that are inevitably present in breast cancer samples. 
To investigate CDK8/19 expression in situ in normal, pre-neoplastic and malignant breast 
tissues, we have carried out immunohistochemistry (IHC) analysis of tissue arrays from 
formalin-fixed, paraffin-embedded patient breast biopsies obtained from US Biomax, Inc. 
(BR-243F, BR-952, BR-954, BR-1003, BR-1006, BR-1503, BR-2082, BR-6161, 
BR-10010). Following washing, epitope unmasking, and peroxidase blocking, the arrays 
were incubated overnight at 4°C with the primary antibody against CDK8 (Santa Cruz 
sc-1521, goat polyclonal, 1:250 dilution) using Antibody Amplifier (ProHisto, LLC). This 
sc-1521 antibody reacts not only with CDK8 but also with CDK19 [5]. Polymer-based anti-
goat secondary antibody (EnVision System-HRP kit, DakoCytomation) was used according 
to manufacturer’s protocol. For antigen detection, all slides were incubated for exactly the 
same length of time with chromogenic substrate DAB (3,3'-Diaminobenzidine) and 
counterstained with methyl green. To evaluate antigen expression, double-blinded semi-
quantitative ImmunoReactivity Scoring (IRS) was performed microscopically with 10 × and 
40 × objectives in accordance with the German Immunohistochemical Scoring System [21] 
by two independent observers, with satisfactory concordance. Some patients’ samples were 
Broude et al. Page 3













repeated on more than one tumor array and the scores for repeating samples were averaged 
in the final scoring pool. A total of 496 normal, hyperplastic, benign and malignant breast 
samples were scored.
Fig. 1a–f shows representative images of CDK8/19 staining in normal, hyperplastic, benign 
and cancerous mammary tissues. The IHC scores for epithelial cell staining in all the 
samples are compiled in Fig. 1g. The significance of differences between the IRS values of 
different categories of tissues was obtained by the chi square test. This analysis showed that 
the average CDK8/19 staining intensity is significantly higher in primary invasive ductal 
carcinomas (IDC) than in other types of breast cancer and in benign, hyperplastic or normal 
mammary tissues. The intensity of CDK8/19 staining varied among the IDC samples (Fig. 
1d–f). The strongest CDK8/19 staining was observed in IDC tumor cells although stromal 
cells also stained positively for CDK8/19 (Fig. 1d–f). Based on this analysis, we conclude 
that CDK8/19 protein expression is elevated in IDC, the predominant type of breast cancer, 
and that tumor cells are likely to constitute the principal source of CDK8 mRNA in breast 
cancer microarrays.
The finding of elevated CDK8/19 expression in IDC relative to normal mammary tissues 
suggest a possible oncogenic role of CDK8 and its interacting genes in breast cancer. 
Indeed, Xu et al. [22] very recently reported that CDK8 is implicated in breast 
carcinogenesis and that the expression of CDK8 protein (or, more precisely, CDK8/19, since 
these authors used the same cross-reactive antibody as in our study) is positively correlated 
with tumor status, nodal metastasis and stage in breast cancer. CDK8 gene expression was 
found to be elevated by Skp2 SCF complex that promotes the ubiquitination and degradation 
of histone variant macroH2A, a negative regulator of CDK8 expression [15]. The oncogenic 
role of CDK8 in breast cancer was suggested to be due to CDK8 facilitating the degradation 
of cell cycle inhibitor p27 [22].
GENETIC ALTERATIONS OF CDK8 GENE COMPLEX IN BREAST CANCERS
CDK8 and CDK19 do not function in isolation but require CCNC binding for their kinase 
activity; CDK8/19-CCNC complex is also associated with MED12 and MED13 in the CDK 
module of the Mediator. We have queried genetic alterations of CDK8, CDK19, CCNC, 
MED12 and MED13 in the TCGA sequence data of 968 breast cancers using cBio Cancer 
Genomics Portal [23, 24]. As shown in Fig. 1H, the most frequently altered gene in this set 
is MED13 (located on chr 17q23 according to Ensembl), which is altered in 11% of breast 
cancers, with gene amplification being by far the most common change (94/968 or 9.7%). 
This exceptionally high rate of gene amplification was associated with higher MED13 
expression at the RNA level in samples with MED13 gene amplification (p = 1.1E-09, 
RNA-seq data). Gene amplification was also the most frequent alteration of CDK8 (chr 
13q12), CDK19 (chr 6q21) and CCNC (chr 6q16.2), with 5 of 14 CDK8-amplified cases 
also showing MED13 amplification, and 10 of 21 CDK19-amplified cancers also amplifying 
CCNC. In contrast to the other members of the CDK module, the most common alterations 
of MED12 (chr Xq13) were point mutations.
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EXPRESSION OF CDK8 AND ITS INTERACTIVE GENES IS ASSOCIATED 
WITH SHORTER RELAPSE-FREE SURVIVAL AND FAILURE OF ADJUVANT 
SYSTEMIC THERAPY IN DIFFERENT BREAST CANCER SUBTYPES
We have extended our previous meta-analysis of Affymetrix microarray data for survival 
correlations of CDK8 expression [11]. Breast cancer datasets were identified in GEO (http://
www.ncbi.nlm.nih.gov/gds) using the GEO platform IDs "GPL96", "GPL570", "GPL571", 
"GPL6947" and "GPL4133" and the keywords "breast", "cancer" and "survival". The 
following datasets were used: GSE1456, GSE2034, GSE2990, GSE3494, GSE4922, 
GSE6532, GSE7390, GSE11121, GSE12093, GSE5327, GSE9195, GSE16391, GSE12276, 
GSE2603, GSE17705, GSE21653, GSE16446, GSE17907, GSE19615, GSE20685, 
GSE20711, GSE26971, GSE31448, GSE31519, E-MTAB-365, GSE20194, GSE20271, 
GSE32646, GSE18728, GSE23988, GSE41998, GSE16716, E-TABM-43, GSE25066, 
GSE42568, GSE45255, GSE37946, GSE4611, GSE46184, GSE22093. The database was 
constructed as described previously [18]. Only datasets including at least 30 patients were 
considered, all together 3,491 breast cancer patients with Affymetrix HGU array data were 
processed. The average relapse-free survival of these patients is 6.3 years, 77% of the 
patients are ER positive and 31% are lymph node positive. 2,015 patients were known to 
receive systemic therapy after sample collection for microarray analysis and 1,000 received 
no systemic therapy.
We analyzed the correlations of CDK8 expression (Affymetrix dataset 204831_at) with RFS 
in all breast cancers and in their major molecular subtypes: luminal A, luminal B, basal and 
HER2+ using KM-plotter online survival analysis tool [25] as described previously [26]. 
Kaplan-Meier plots in Fig. 2 show that higher CDK8 expression was significantly associated 
with shorter RFS in all cancers and in each of the four subtypes. This correlation was 
validated in an independent TCGA RNA-Seq dataset (see below) and by the recent study of 
Xu et al. [22] who found that CDK8/19 protein expression significantly predicted disease-
specific and metastasis-free survival.
We have also analyzed survival associations in the subsets of systemically untreated patients 
and systemically treated patients in all cancers and patients who were exposed to adjuvant 
systemic therapy after surgery (when the samples were collected for microarray analysis) 
within each of the molecular subtypes (except for the smallest HER2+ dataset). The RFS 
correlations of CDK8 expression were very different between the treated and the untreated 
patients. Higher CDK8 was weakly associated with shorter RFS among the untreated 
cancers in the luminal A category and showed no significant association for the untreated 
luminal B and basal cancers. In contrast, the CDK8/RFS association was very strong for the 
systemically treated categories of each subtype (Fig. 2), suggesting that higher CDK8 
expression is associated primarily with the failure of systemic adjuvant therapy rather than 
with tumor relapse that would result from treatment-unrelated phenotypes. Higher CDK8 
expression was associated with shorter survival of all breast cancer patients in respect not 
only to RFS but also to Distant Metastasis Free Survival (DMFS) (HR=1.51, p=9.9E-05) 
and, to a lesser extent, to Overall Survival (OS) (HR=1.41, p=0.0044). The preferential 
association of CDK8 with the survival of treated rather than untreated breast cancer patients 
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was also obvious for DMFS (HR=1.43, p=0.036 for untreated and HR=2.01, p=2.5e-05 for 
treated patients) but was not observed in the smaller datasets that were available for OS 
(data not shown).
The above observations suggest that CDK8 expression per se plays little role in the relapse 
of luminal B and basal cancers in the absence of treatment but it is strongly associated with 
the failure of systemic therapy. Since these cancers are largely treated with conventional 
chemotherapeutic drugs, the observed association dovetails with our previous report that 
CDK8 is a key mediator of chemotherapy-induced tumor-promoting paracrine activities and 
that CDK8 inhibition sensitizes tumors to chemotherapy [11]. On the other hand, the 
associations observed in the estrogen receptor (ER) positive tumors of the most common 
luminal A subtype cannot be so readily explained by the previous data. Such tumors 
typically receive endocrine therapy, with or without chemotherapy, and the strong 
correlation between CDK8 expression and the therapy failure observed in this subtype 
would suggest a possible role for CDK8 in the response to endocrine therapy. In addition, 
the finding that CDK8 is associated with shorter RFS even in the untreated luminal A 
cancers (but not in the other subtypes) also suggests a functional link between CDK8 and 
ER. Based on these findings, we are conducting experimental analysis of the possible role of 
CDK8 in the ER transcriptional activity.
One could expect that CCNC and possibly also CDK19, MED12 and MED13 could display 
prognostic associations that would be similar to those observed for CDK8. We have 
analyzed the survival impact of these genes using the following Affymetrix probesets 
selected using JetSet [27]: CCNC, 201955_at; MED12, 216071_x_at; CDK19 (CDC2L6), 
212899_at; MED13, 201987_at; TOP2A, 201292_at; MYC, 202431_s_at. Fig. 2b shows 
Kaplan-Meier plot analysis of CDK19, CCNC, MED13 and MED12 in all the breast cancer 
patients as well as in the treated and the untreated patient datasets. The results for CDK19, 
CCNC and MED13 (Fig. 3) are remarkably similar to those observed for CDK8 (Fig. 2), 
with higher expression of these genes associated with shorter RFS among all breast cancers 
(including the individual molecular subtypes, not shown) and a much stronger association 
among the treated than among the untreated patients. The concurrence among different 
members of CDK8/19-CCNC complex confirms the association with treatment failure 
observed for CDK8. Surprisingly, MED12 expression showed the opposite prognostic 
association, with higher MED12 associated with longer RFS, both in the treated and in the 
untreated patients (Fig. 3).
It is instructive to compare the above RFS associations obtained for CDK8 and its 
interactive genes, which are not directly involved in cell proliferation, with the correlations 
observed for TOP2A, a proliferation marker expressed primarily in cycling cells [28]. Such 
cell-proliferation genes comprise a major component of multigene lists used for RNA-based 
breast cancer diagnostics, such as MammaPrint [29]. TOP2A, in particular, was found in an 
earlier analysis to be a very strong negative predictor of RFS in the total set of breast cancers 
[20]. As shown in Fig. 3, higher TOP2A is strongly associated with lower RFS in all breast 
cancers but in contrast to CDK8, CDK19, CCNC or MED13, this association was 
independent of treatment, suggesting that higher proliferation is a treatment-independent 
negative prognostic marker. We also noted that higher TOP2A expression was associated 
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with shorter RFS in luminal A (HR=2.24, p<1E-16) and luminal B subtypes (HR=1.79, 
p=1.6E-06), but TOP2A shows no significant survival associations in basal cancers, whereas 
higher TOP2A shows the opposite association with longer RFS in the HER2+ subtype 
(HR=0.54, p=0.0035). Hence, the prognostic correlations of CDK8 and its interactive genes 
in breast cancer are drastically different from those that are observed with a proliferation-
specific gene.
The correlations between the expression of CDK8 and its interactive genes with negative 
prognosis in breast cancer were validated through the analysis of the TCGA RNA-Seq 
dataset of 618 patients. RNA-seq data for breast cancer samples [30] were published in The 
Cancer Genome Atlas (TCGA) of the National Cancer Institute (http://
cancergenome.nih.gov/). We have downloaded the pre-processed level 3 data generated by 
the Illumina HiSeq 2000 RNA Sequencing Version 2 platform. For each of these samples, 
gene expression was determined using a combination of MapSplice and RSEM. The 
individual patient files were combined in R using the plyr package [31]. Using the same 
analysis as for the Affymetrix dataset, we found that shorter RFS was associated with higher 
expression of CDK19 (HR=3.2, p=0.0051), CDK8 (HR=2.0, p=0.017) and CCNC (HR=2.2, 
p=0.04), but no significant correlations were observed for MED12 and MED13 in this 
dataset.
CORRELATIONS OF CDK8 EXPRESSION IN BREAST CANCERS WITH ITS 
INTERACTIVE GENES AND MYC
We have asked if the observed similar and dissimilar RFS associations for CDK8 versus its 
interactive genes could reflect positive or negative correlations of the expression levels of 
these genes among breast cancer samples. To simplify the correlation analysis, all 3,491 
samples were arranged by their CDK8 signal values and separated into 35 bins of 100 
tumors (91 tumors in the last bin). The median CDK8 expression levels for these 35 bins 
were plotted against the median expression levels of CDK19, CCNC, MED12 and MED13 
(Fig. 4a). This analysis revealed striking positive correlations between the expression levels 
of CDK8 and those of CDK19, CCNC and MED13 but a negative correlation with MED12 
expression (Fig. 4a). The corresponding R2 correlations for the 35 bins and the P-values 
(determined for all 3,491 samples by Spearman rank correlation) are shown in Fig. 4a. The 
positive correlations between the expression of CDK8, CDK19 and their interactive proteins 
CCNC and MED13 suggest the existence of common regulatory mechanisms or common 
selection pressures that define the expression of these genes in cancers. CDK8, CDK19, 
CCNC and MED13 also share the same association with RFS in breast cancers: a very 
strong association with shorter RFS in systemically treated but not in the untreated patients 
(Figs 2 and 3). This common predictive pattern between CDK8, its kinase isoform and their 
interactive proteins provides a strong independent confirmation of the association between 
CDK8 expression and the failure of adjuvant therapy.
MYC oncogene is frequently amplified or overexpressed in breast cancers and MYC 
amplification is significantly correlated with aggressive tumor phenotypes and poor clinical 
outcomes [32]. CDK8 was shown to regulate MYC protein and downstream MYC target 
gene expression in colon cancer [16], and we have asked if CDK8 expression in breast 
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cancers would correlate with the expression of MYC. CDK8 expression in breast cancers 
showed a very strong positive correlation with MYC expression, when the tumor samples 
were distributed into bins according to the expression of either CDK8 or MYC (Fig. 4a), 
suggesting that CDK8 may also regulate MYC in breast cancers.
ELEVATED EXPRESSION OF CDK8, CDK19, CCNC AND MYC IS 
ASSOCIATED WITH P53 MUTATIONS
We have also investigated if the expression of CDK8 and its interactive genes correlates 
with the p53 mutation status, using Affymetrix microarray gene expression data in 319 
patients with known p53 status, as described [33]. The results, presented in Fig. 4b, show 
that p53 mutations were associated with a striking increase in the expression of CDK8, 
CDK19 and CCNC and with a decreased MED12 expression, whereas MED13 expression 
was unaffected by the p53 status. Importantly, MYC expression is known to be upregulated 
by p53 mutations [34], and our analysis in breast cancers (Fig. 4b) confirmed these 
observations. These findings raise a question if p53 mutations may regulate the expression 
of CDK8 and its interactive proteins, just as K-RAS mutations activate CDK8 expression in 
pancreatic cancers [35].
CDK8-MED12 DICHOTOMY IN BREAST CANCER
The above-described analyses provided a surprising conclusion that the two Mediator 
subunits that interact with CDK8/19-CCNC in the CDK module of the Mediator showed the 
opposite correlations with CDK8 expression and survival. While MED13 expression was 
positively correlated with that of CDK8, CDK19 and CCNC, MED12 expression was 
negatively correlated with CDK8 expression and MED12, in contrast to CDK8, CDK19, 
CCNC and MED13 was associated with positive prognosis in breast cancers. In addition, the 
p53 mutant status was associated with lower MED12 expression, in contrast to the higher 
expression of CDK8, CDK19 and CCNC. Furthermore, the most common type of genetic 
changes associated with MED12 in breast cancer is point mutations rather than gene 
amplification as for the other members of the CDK module.
Whereas MED13 links the CDK module with the rest of Mediator, MED12 was shown to 
stimulate the CDK8 kinase activity within the CDK module [36]. On the other hand, 
MED12, in contrast to CDK8, is found not only in the nucleus but also in the cytoplasm, 
where MED12 was shown to interact with TGFβR2 and to inhibit the TGFβ pathway, an 
activity independent of the role of the nuclear MED12 in the transcriptional Mediator 
complex [37]. Furthermore, while MED12 displays tumor-promoting activities in prostate 
cancer [38], it undergoes loss-of-function mutations in uterine leiomyomas [39]. 
Remarkably, the same MED12 mutations were also found and characterized in breast 
fibroadenomas [40] and benign phyllodes tumors of the breast [41, 42] but in the case of the 
fibroadenomas these mutations (which are different from those found in the TCGA breast 
cancer panel) occurred not in the epithelial mammary cells but rather in the stromal tissue, 
where they were associated with dysregulated estrogen signaling and extracellular matrix 
organization [40]. In light of these findings, one should consider the possibility that higher 
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MED12 expression that we found to be associated with positive prognosis in breast cancer 
microarray samples may reflect the stromal cell contribution.
CONCLUSIONS
In summary, the present analysis demonstrates that the previously observed [11] strong 
association between higher expression of CDK8, CDK19 and CCNC with shorter RFS in 
breast cancer is due primarily to the association of the CDK8 complex with the failure of 
adjuvant therapy, which should be due at least in part to the role of this transcription 
regulatory complex in chemotherapy-induced tumor-promoting paracrine activities [11]. The 
results of our analysis warrant further investigation of the validity of CDK8 and its 
interacting genes as a new class of cancer biomarkers that may predict relapse-free survival 
after systemic therapy.
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CDK19 cyclin-dependent kinase 19
CDK8 cyclin-dependent kinase 8
CTD C-terminal domain
CYP2D6 cytochrome P450 2D6
DMFS distant metastasis free survival
ER estrogen receptor
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GEO Gene Expression Omnibus
HR hazard ratio





Pol II RNA polymerase II
RARA Retinoic acid receptor alpha
RFS relapse-free survival
STAT3 signal transducer and activator of transcription 3
TCGA The Cancer Genome Atlas
TGFβ transforming growth factor beta
TGFβR2 receptor 2 of transforming growth factor beta
TIMP-1 tissue inhibitor of metalloproteinase 1
TOP2A topoisomerase 2 alpha
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CDK8/19 protein expression and genetic alterations of CDK module components in breast 
cancers. A–F: representative images of CDK8/19 IHC staining in different types of 
mammary tissues. Left: H&E staining, 10 × objective. Center: CDK8/19 IHC (DAB) with 
methyl green counterstain, 10 × objective, Right: same as center, 40 × objective. A. Normal 
breast tissue; B. Epithelial hyperplasia; C. Lobular carcinoma; D–F. Infiltrating ductal 
carcinoma, not otherwise specified (3 different tumors); G: IHC scores for different types of 
mammary tissue samples. H: genetic alterations of CDK8, CDK19, CCNC, MED12 and 
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MED13 in TCGA panel of 968 breast cancers; only cancers showing alteration in any of 
these genes are presented. Numbers indicate the combined frequency of all genetic 
alterations for each gene. Red: gene amplification. Blue: homozygous deletion. Green: point 
mutation.
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Association of CDK8 expression with RFS in Affymetrix breast cancer microarray data 
determined using KM-plotter online survival analysis tool (http://kmplot.com/analysis/) with 
“Auto select best cutoff” option. The results are shown for all breast cancers and their 
molecular subtypes, including subsets that did not receive or received systemic therapy after 
sample collection. Note that the sums of the patient numbers in individual subtypes are less 
than the number of all patients, since the molecular subtype or the treatment status was not 
reported for every patient.
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Association of CDK19, CCNC, MED12, MED13 and TOP2A expression with RFS in 
Affymetrix breast cancer microarray data, plotted for all patients and the subsets that did not 
receive or received systemic therapy.
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Intergenic correlations of the expression of CDK8 and its interactive genes in Affymetrix 
breast cancer microarray data. (A) Pairwise correlations of expression levels for the 
indicated genes in 3,491 cancers: median expression plotted for 35 bins of 100 samples 
assembled into bins according to the levels of the first gene (X-axis); the second gene 
(median expression in the bin shown on the Y-axis) is labeled at the top of each graph. p-
values are based on Spearman rank correlation. (B) Expression levels of the indicated genes 
in p53 wild-type and p53-mutant tumors in 319 patients with known p53 status. The 
columns represent the average gene expression; the error bars represent the 95% confidence 
interval. p-values are based on Mann-Whitney U-test.
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